- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Athira Pharma GAAP EPS of -$1.68 | 12 | Seeking Alpha | ||
| 03.10. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 11.09. | Athira Pharma announces 10-for-1 reverse stock split | 11 | Seeking Alpha | ||
| 11.09. | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | 235 | GlobeNewswire (Europe) | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| 11.09. | Athira Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 07.08. | Athira Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Athira Pharma, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.05. | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | 544 | GlobeNewswire (Europe) | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen | |
| 06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 611 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| PALATIN TECHNOLOGIES | 20,620 | +43,29 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| MAINZ BIOMED | 0,986 | -6,94 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika
18.11.2025... ► Artikel lesen | |
| INFLARX | 1,031 | +1,88 % | InflaRx reports positive phase 2 results for HS and CSU treatments | ||
| VIKING THERAPEUTICS | 29,745 | +0,03 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| ABIVAX | 103,20 | -0,19 % | Abivax gains amid takeover speculation | ||
| GERON | 0,988 | +1,15 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| VIDAC PHARMA | 0,502 | 0,00 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,820 | +0,36 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| GALAPAGOS NV | 26,600 | +0,08 % | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| CARDIFF ONCOLOGY | 1,750 | -1,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,011 | +0,80 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,920 | 0,00 % | Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results | BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| CYTOKINETICS | 57,00 | 0,00 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
Das Unternehmen ATHIRA PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,32 % bei einem Aktienkurs von 4,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.